Clinical Trial Update: Single-agent Cobimetinib for Adults With Histiocytic Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cobimetinib as a single agent for adults with histiocytic disorders has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Histiocytic Disorders

Drugs mentioned

• Cobimetinib (cobimetinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Histiocytic Disorders | Phase 2 | Status: COMPLETED | Results posted: 2023-11-18